ME (23andMe Holding Co.) Earnings growth in current year

ME (23andMe Inc) - company brandmark

Cloud-based delivery of genetic reports minimizes logistics costs. The YoY EPS percentage shift confirms this operational efficiency, where the value of 0.00 expresses the metric level. The leadership of 23andMe Holding Co. (ME) in personal genomics provides access to the drug development market, however, strict austerity and patent monetization during the restructuring period will be the determining factors for future growth.

ME - 23andMe Inc Earnings growth in current year over the range 07/04/2022 - 04/05/2025

Financial and market metric breakdowns for 23andMe Inc (ME)

- price and consensus price forecast:
Summary company analysis:23andMe Inc. (ME)
Core merchandise of 23andMe Inc.

The expansion of 23andMe Holding Co. (ME) partnerships with pharmaceutical giants in the search for drug targets is directly reflected in the shift in earnings per share compared to last year. This indicator measures the annual dynamics of net income per share, revealing the pace of genetic data monetization. While the positive trend confirms a fundamental business turnaround, stagnation in this metric signals risks of capital freeze.

Direct competitors

Net earnings per share change in current year Agilent Tech A|Earnings per share growth in current year Quest Corp|Illumina, Inc. (ILMN) - Expected net earnings per share growth this year|Earnings growth in current year EXAS|RVTY (Revvity) - Earnings per share increase in current year|Earnings per share growth in current year bio-rad.com BIO|NNNN: Earnings per share growth this year|Sotera Health Corp - Earnings growth in current year|Expected net earnings per share growth this year QuidelOrtho QDEL|OPK (OPKO Health) - Net earnings per share growth this year|Earnings per share growth rate in current year CareDx, Inc. (CDNA)|Net earnings per share growth this year MRVI|Earnings per share growth rate in current year Fulgent FLGT|Earnings per share growth in current year Standard BioTools Inc. (LAB)|CTKB (Cytek Biosciences, Inc.) - Earnings per share increase in current year|Earnings growth in current year OSUR (OraSure Corp)|Expected net earnings per share growth this year Exagen Inc. (XGN)|MDXH: Net earnings per share growth this year|Expected net earnings per share growth this year Lucid Diagnostics Inc LUCD|PRE (Prenetics Global Ltd) - Net earnings per share growth this year|Net earnings per share growth this year Insight Molecular|TRIB (Trinity Biotech) - Earnings growth in current year|Earnings per share growth in current year PRPH|Earnings growth in current year AIMD|Net earnings per one share growth for the current year CODX|Earnings per share growth in current year Heart Test Laboratories HSCS|BMRA: Earnings per share growth this year|CDIO - Earnings per share growth in current year|Onconetix Corp (ONCO) - Net earnings per share growth this year|VRAX (Virax Biolabs Group Ltd) - Net earnings per share growth this year|Earnings per share growth rate in current year Bluejay Diagnostics Corp (BJDX)|AWH (Aspira Women's Health, Inc.) - Earnings growth in current year|AXDX - Net earnings per share change in current year|Earnings per share growth in current year centogene.com (CNTG)|Expected net earnings per share growth this year Enzo Biochem|Expected net earnings per share growth this year FRES|Net earnings per share change in current year GTG Labs|Psychemedics Inc - Earnings growth in current year